Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03482557|
Recruitment Status : Active, not recruiting
First Posted : March 29, 2018
Last Update Posted : February 9, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Device: CESM Device: MRI||Not Applicable|
Mammography is the main way to help find breast cancers early so they can be treated. Unfortunately, mammography does not work as well in women who have dense breast tissue or who are at high-risk for breast cancer. In these women, breast MRI is also used to help find breast cancers.
Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone. This is similar to breast MRI.
For this study, participants who are already getting a breast biopsy will have a contrast enhanced mammogram and a breast MRI before the biopsy. The participant's contrast enhanced mammogram and breast MRI images will then be included within a large collection of images. Radiologists will compare the images to see if the contrast enhanced mammograms and the breast MRI find the same number of breast cancers. If the investigators find they perform similarly, then contrast mammography may be used to aid in breast cancer screening in the future.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||82 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening|
|Actual Study Start Date :||May 17, 2018|
|Estimated Primary Completion Date :||August 30, 2023|
|Estimated Study Completion Date :||August 30, 2023|
Experimental: CESM VS MRI
Each enrolled participant will receive both a CESM and MRI exam prior to the breast biopsy, if they had not been performed already as part of clinical care.
MRI: Breast MRI will be performed, if not already performed as part of clinical care.
CESM: After the MRI is complete, patients will be brought to the mammography department for the contrast enhanced mammogram. The CESM will only occur if not already performed as part of the patient's clinical care.
Biopsy: Patients will then have their biopsy. Any additional findings seen on the CESM or MRI will be worked up also.
Reader Study: The CESM and the MRI images will be included in a case set that is ready by 10 study radiologists at a later date, after the biopsy is performed. These radiologists will look at the images to see if CESM and MRI find the same number of breast cancers.
Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
Other Name: Contrast Enhanced Spectral Mammography
MRI uses magnets to create a detailed image of the tissues and bones inside of the body
Other Name: Magnetic Resonance Imaging
- Diagnostic accuracy of CESM compared with breast MRI for breast cancer screening [ Time Frame: 2 years ]We will determine whether CESM is non-inferior to breast MRI for breast cancer detection by comparing cancer detection rates on both studies using a multi-case multi-reader study model.
- Diagnostic accuracy of CESM compared with abbreviated MRI for breast cancer detection [ Time Frame: 2 years ]We will determine whether CESM is non-inferior to abbreviated breast MRI for breast cancer detection by comparing cancer detection rates on both studies using a multi-case multi-reader study model.
- Diagnostic accuracy of CESM compared with conventional mammography for breast cancer screening [ Time Frame: 2 years ]We will determine whether CESM is superior to conventional 2D mammographic screening using a multi-case multi-reader study model.
- Patient preference for breast MRI versus CESM for breast cancer screening [ Time Frame: 2 years ]We will provide each patient with a survey following completing of the CESM and MRI exams to understand which exam the patients prefer for breast cancer screening
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||30 Years to 110 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
Prospective Patient Recruitment
- Age > or equal to 30 years
- Recommendation for breast biopsy has been made
- Recommendation for biopsy will result from an imaging work-up originating with a screening exam (mammogram, tomosynthesis, ultrasound, or MRI) that was within 3 months of biopsy.
Reader Study Inclusion Criteria:
- CESM and MRI exam performed within 3 months of one another.
- CESM and breast MRI exams must be performed as part of imaging work-up based on a screening exam of any type (mammography, tomosynthesis, ultrasound, and MRI)
- CESM studies will include at least four low energy and four recombined images (LCC, LMLO, RCC, RMLO).
- MRI exams will include at least fluid sensitive sequence, multi-phase T1-weighted
Prospective Patient Recruitment
- Women with implants
- Participants who have a known allergy to contrast media.
- Participants who have a known severe allergic response to one or more allergens, defined as anaphylaxis
- Participants with poor asthma control using the National Heart, Lung, and Blood Institute guidelines as defined by:
Symptoms > 2 days per week Short-term beta agonist use > 2 days per week Nighttime awakenings > 2 times per month
- Participants with Renal insufficiency or failure, as determined by GFR < 60 mL/min/1.73 m2 , performed for all patients within 24 hours of the imaging exams
- Participants who are pregnant. Pregnant women are excluded from this study due to the radiation dose from the CT scan and its potential teratogenic effects on the fetus.
- Participants who are breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to contrast administration in the mother.
- Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrythmia, or severe cardiomyopathy. These underlying medical conditions may make the participant more likely to develop a contrast reaction. This is based on the ACR contrast manual version 10.3 and hospital policy.
- Participants with a concurrent active illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thyroid storm.
- Participants with thyroid carcinoma or thyroid disease for whom systemic radioactive iodine therapy is part of planned diagnostic work-up or treatment within 2 months following the contrast mammogram study.
- Participants with non-MR compatible objects or implants that would make MRI a contraindication.
- Participants who have a pacemaker, pacer wires, implantable defibrillator, or implanted monitoring device.
- Participants with intracranial clips, metal implants or external clips within 10 mm of the head.
- Participants who have had a metal injury to the eye.
Reader Study Exclusion Criteria:
- Imaging sets with implants.
- Imaging sets in which a biopsy or surgical intervention was performed since the most recent screening exam, prior to acquisition of the study MRI or CESM.
- Imaging sets in which a biopsy was recommended, but biopsy was not performed and 2 year imaging follow-up is not available
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03482557
|United States, Massachusetts|
|Beth Israel Deaconess|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Vandana Dialani, MD||Beth Israel Deaconess Medical Center|
|Responsible Party:||Vandana Dialani, MD, Principal Investigator, Dana-Farber Cancer Institute|
|Other Study ID Numbers:||
|First Posted:||March 29, 2018 Key Record Dates|
|Last Update Posted:||February 9, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Product Manufactured in and Exported from the U.S.:||No|
contrast enhanced spectral mammography
Neoplasms by Site